Alexion Pharmaceuticals (NASDAQ:ALXN) – Investment analysts at Piper Jaffray upped their Q1 2018 EPS estimates for Alexion Pharmaceuticals in a research report issued to clients and investors on Friday, April 13th. Piper Jaffray analyst C. Raymond now forecasts that the biopharmaceutical company will earn $1.25 per share for the quarter, up from their previous forecast of $1.23. Piper Jaffray also issued estimates for Alexion Pharmaceuticals’ FY2018 earnings at $6.02 EPS.
A number of other brokerages have also commented on ALXN. Deutsche Bank set a $161.00 price target on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, March 15th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $149.00 price objective (up from $147.00) on shares of Alexion Pharmaceuticals in a research note on Friday, March 16th. Robert W. Baird set a $160.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. Nomura lifted their target price on Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. Finally, BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, March 17th. Two analysts have rated the stock with a sell rating, two have given a hold rating and twenty have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $155.95.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the business earned $1.26 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 13,245 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the sale, the chief executive officer now directly owns 131,425 shares of the company’s stock, valued at $15,286,041.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John B. Moriarty sold 1,261 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $147,864.86. Following the sale, the executive vice president now directly owns 20,210 shares in the company, valued at $2,369,824.60. The disclosure for this sale can be found here. Insiders sold 28,700 shares of company stock worth $3,345,708 over the last 90 days. Company insiders own 4.35% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB lifted its holdings in Alexion Pharmaceuticals by 9.0% during the fourth quarter. Xact Kapitalforvaltning AB now owns 45,832 shares of the biopharmaceutical company’s stock worth $5,481,000 after buying an additional 3,789 shares during the period. CNB Bank acquired a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at $150,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Alexion Pharmaceuticals by 9.5% in the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 103,254 shares of the biopharmaceutical company’s stock valued at $12,348,000 after acquiring an additional 8,997 shares during the period. Delek Group Ltd. acquired a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at $10,291,000. Finally, Altman Advisors Inc. acquired a new stake in Alexion Pharmaceuticals during the 4th quarter worth about $1,599,000. Hedge funds and other institutional investors own 95.09% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals (ALXN) Forecasted to Post Q1 2018 Earnings of $1.25 Per Share” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2018/04/17/alexion-pharmaceuticals-alxn-forecasted-to-post-q1-2018-earnings-of-1-25-per-share.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.